Jin Zhang, Ph.D.

Researchers at University of California San Diego have identified a new signaling process involving G protein-coupled receptors (GPCRs), a cellular target already exploited by hundreds of diverse drugs. The discovery, published in the October 26, 2022 issue of Nature, opens the possibility of new therapies, including for multiple forms of cancer.

GPCRs are the largest and most diverse group of membrane receptors in eukaryotes — cells containing a nucleus and other organelles. Residing on the cell’s surface, they act as an inbox for messages arriving in the form of sugars, proteins, lipids and peptides, and play myriad roles in body functions, including fundamentally in regulating communications between cells… Continue reading.

WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Jin Zhang, Ph.D., Professor, Department of Pharmacology, School of Medicine, University of California, San Diego, to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”

Dr. Zhang was nominated, reviewed, and elected by peers and members of the College of Fellows for “outstanding contributions to engineering molecular and photophysical tools that enable the precise interrogation of biochemical networks within living cells.”